Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

Democrats vow to undo Trump’s Medicaid cuts, reverse ACA dismantling

In a victory speech on Nov. 4, Rep. Hakeem Jeffries (D-NY), the presumed next speaker of the House, ran through the bread-and-butter concerns which gave Democrats House and Senate majorities not seen in a generation.

November 06, 2026

Vol.52 No.41

By Paul Goldberg

As Iowa goes blue, incoming Gov. Rob Sand and Sen. Josh Turek offer plans to address the state’s “cancer crisis”

The blue tsunami of the 2026 midterm elections hit few states as dramatically as Iowa, where Democrats flipped one Senate seat, three congressional districts, and the governor’s office.

November 06, 2026

Vol.52 No.41

By Sara Willa Ernst

Community sites have the patients to boost trial enrollment—but not the infrastructure

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Tarlatamab + durvalumab extends survival for patients with aggressive small cell lung cancer, phase III trial finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to the results of the phase III open-label, multicenter, randomized DeLLphi-305 study.

November 06, 2026

Vol.52 No.41

Clinical Roundup

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase III open-label, multicenter, randomized DeLLphi-305 study.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors.

October 30, 2026

Vol.52 No.40

Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

YOU MAY BE INTERESTED IN

Democrats vow to undo Trump’s Medicaid cuts, reverse ACA dismantling

As Iowa goes blue, incoming Gov. Rob Sand and Sen. Josh Turek offer plans to address the state’s “cancer crisis”

Community sites have the patients to boost trial enrollment—but not the infrastructure

Tarlatamab + durvalumab extends survival for patients with aggressive small cell lung cancer, phase III trial finds

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login